HomeNewsGlobal Pharma

Johnson & Johnson Submits sBLA to FDA for Approval of DARZALEX FASPRO-Based Quadruplet Regimen

Johnson & Johnson Submits sBLA to FDA for Approval of DARZALEX FASPRO-Based Quadruplet Regimen

Johnson & Johnson has submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for approval of a new indication for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) for whom autologous stem cell transplant (ASCT) is deferred or who are ineligible for ASCT. 

This submission is supported by data from the Phase 3 CEPHEUS study (NCT03652064), which showed that 60.9 percent of patients achieved minimal residual disease (MRD)-negativity with D-VRd and the risk of progression or death was reduced by 43 percent.

The CEPHEUS study evaluated the efficacy and safety of D-VRd compared to bortezomib, lenalidomide and dexamethasone (VRd) for NDMM patients for whom ASCT was not planned as initial therapy (transplant ineligible or deferred).

The D-VRd regimen increased depth and durability of responses compared to VRd, including the primary endpoint of overall MRD-negativity rate (10-5) of 60.9 percent vs 39.4 percent at a median follow-up of 58.7 months (odds ratio [OR], 2.37; 95 percent confidence interval [CI], 1.58-3.55; P<0.0001). The sustained MRD-negativity rate favored D-VRd 48.7 percent vs 26.3 percent for VRd (P<0.0001).

The study also demonstrated that D-VRd significantly reduced the risk of progression or death by 43 percent (hazard ratio, 0.57; 95 percent CI, 0.41-0.79; P<0.0005) vs VRd and achieved an overall complete response (CR) or better rate of 81.2 percent with D-VRd vs 61.6 percent with VRd (P<0.0001). The overall safety profile of D-VRd was consistent with the known safety profiles for DARZALEX FASPRO and VRd.

"DARZALEX FASPRO-based therapies continue to be at the forefront of multiple myeloma research. We're encouraged that the FDA Oncologic Drugs Advisory Committee recently voted in favor of MRD-negativity as an acceptable endpoint in multiple myeloma trials. CEPHEUS is the first registrational study with a primary endpoint of MRD-negativity filed by Johnson & Johnson in multiple myeloma," said Craig Tendler, MD, Vice President, Late Clinical Development and Global Medical Affairs, Innovative Medicine, Johnson & Johnson.

"The data from CEPHEUS add to the body of evidence for DARZALEX FASPRO in newly diagnosed multiple myeloma and, together with the results of the PERSEUS study, demonstrate the potential benefit of this quadruplet regimen for newly diagnosed patients, regardless of transplant eligibility," Tendler added.

More news about: global pharma | Published by Aishwarya | October - 01 - 2024

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members